A new policy document issued by the State Council aims to improve the market-based drug pricing mechanism, with significant positive implications for the innovative drug sector. The guidelines emphasize leveraging market forces in resource allocation while enhancing government oversight to serve the development of a unified national pharmaceutical market, support high-quality industry growth, and ensure public access to effective and affordable medicines.
The document outlines 14 measures across four key areas: refining pricing policies for critical processes, enhancing price discovery by relevant entities, guiding reasonable pricing in key sectors, and strengthening overall price governance. Specific measures include optimizing initial pricing mechanisms for newly launched drugs such as innovative medicines, utilizing medical insurance payment standards to guide pricing, improving volume-based procurement pricing systems, and enhancing listed price management.
Furthermore, the policy encourages various stakeholders—including medical institutions and pharmacies—to participate in price formation, promotes diversified payment methods for innovative drugs, ensures supply and price stability for scarce medicines, and strengthens oversight of narcotics and psychotropic drug pricing. It also introduces risk warning systems, addresses irrational bidding practices, and establishes a medical insurance value assessment framework to maintain reasonable price levels.
Market analysts view the new guidelines as a significant opportunity for the pharmaceutical industry, particularly innovative drug developers. Experts note that truly innovative drugs will enjoy greater pricing flexibility, with companies using self-assessment tools to set initial prices. Higher innovation levels will grant more autonomy, and subsequent medical insurance negotiations are expected to be more adaptable. A dual-track system is also introduced, allowing negotiated drugs supplied to non-insurance medical institutions to be priced independently, creating a secondary market for pricing. Additionally, a commercial insurance drug directory will open new payment channels for high-cost, high-value medications.
Securities firms highlight that investment in the pharmaceutical sector should increasingly focus on clinical value—addressing patient and clinical needs. Both domestic insurance policies and global expansion strategies are placing greater emphasis on clinical benefits. Key segments看好 include the innovative drug supply chain and advanced medical devices. Industry performance is projected to improve by early 2026, with leading innovative drug companies expected to see accelerated commercial expansion and revenue from licensing agreements. The CRO/CDMO sector may also experience steady growth, driven by recovering investments and the rapid commercialization of blockbuster drugs like GLP-1 therapies. Medical device segments, including imaging and consumer healthcare, are showing signs of recovery, while some API, traditional medicine, and healthcare service providers continue to face challenges.
After a decade of innovation-driven transformation, China’s pharmaceutical industry has largely shifted from generic to innovative drug development, with enhanced global expansion capabilities. Looking ahead, sectors such as innovative drugs, brain-computer interfaces, AI healthcare, and surgical robots are expected to remain key growth areas. Opportunities also exist in aging-related and out-of-hospital healthcare consumption, alongside undervalued segments like anesthetics and blood products.
Relevant companies include: - TIGERMED (03347): Reported 2025 revenue of RMB 68.33 billion, up 3.48% year-on-year, with net profit surging 119.15%. Growth was driven by strong overseas clinical operations and recovering domestic innovative drug project demand. New contracts increased by 20.7% to RMB 101.6 billion, reflecting revived clinical CRO demand. - JOINN (06127): Secured new orders worth RMB 2.6 billion in 2025, a 41.3% increase, with Q4 orders hitting a record high. The company is well-positioned in high-growth areas like ADC and antibody therapies and expects double-digit order growth in 2026. - WUXI BIO (02269): Achieved revenue of RMB 217.9 billion in 2025, up 16.7%, with a record 209 new projects—nearly half from the U.S. and two-thirds involving bispecific antibodies and XDC therapies. The company forecasts 13-17% growth in 2026. - WUXI APPTEC (02359): Posted 2025 revenue of RMB 454.56 billion, a 15.84% increase, with net profit jumping 102.65%. Strong performance was driven by chemical and TIDES businesses, with dividends totaling RMB 6.755 billion. - BIOCYTOGEN-B (02315): An AI model trained on exclusive antibody data enables screening of billions of human antibody sequences, improving drug candidate specificity and reducing development risks. The automated system is expected to accelerate the company’s large-scale R&D pipeline.
Comments